DRG uses cookies to improve your experience on this website. Some of the cookies we use are essential for parts of the website to operate. Please be aware that if you continue without changing your cookie settings, you consent to this. For more information on our use of cookies, please review our cookie policy.

Research & Reports

Searching in Biopharma (1947)

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia | Unmet Need | Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)

Thank you!

Your request has been received by DRG. A represantative will contact you shortly to provide more details on the research and data contained in this report and ensure that it will meet your current research needs.

Coming Soon – October 2019

MARKET OUTLOOK

Rituximab-based chemoimmunotherapy regimens (e.g., R-DHAP, R-ICE, R-ESHAP) are the standard of care for relapsed / refractory (R/R) DLBCL, followed by conditioning and ASCT in eligible patients. The CAR T-cell therapies Yescarta and Kymriah have expanded treatment options, although their use is restricted to third and subsequent lines of therapy. In 2018, Keytruda was the first immune checkpoint inhibitor to gain approval in NH L, specifically for R/RPMBCL, a rare subset of DLBCL. Despite the evolving market landscape, significant unmet need remains in R/RDLBCL owing to the limited availability of effective treatment options.

QUESTIONS ANSWERED

  • What are the most important factors that drive hematologist-oncologists’ prescribing decisions for R/RDLBCL?
  • How do current therapies perform on key clinical attributes for R/RDLBCL?
  • What are the major unmet needs and the most lucrative opportunities in R/RDLBCL?
  • When considering new treatment options in this setting, what trade-offs are acceptable to surveyed hematologist-oncologists between key clinical attributes and cost of therapy?

Markets covered: United States, United Kingdom, France, Germany

Primary research: Survey of 60 U.S hematologist-oncologists and 30 European hematologist-oncologists

Key companies: Kite Konnect, Novartis, Merck & Co.

Key drugs: Rituximab, Yescarta, Kymriah, Keytruda

PRODUCT DESCRIPTION

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. Two market scenarios are profiled in detail by DRG experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Detailed, Expanded Analysis: Relapsed or refractory DLBCL - (US-EU)
    • Coming Soon
      • Coming Soon

Already a Client? Log in to access this report.

  • Pub Date: April 2019
  • Author(s): Sudha Malhotra
  • Sudha Malhotra, is an associate analyst in the oncology team at Decision Resource Group. She is responsible for performing secondary market analysis including patent research, pricing, and clinical trial assessment for major pharmaceutical markets covering a wide range of oncology indications. She obtained her doctorate degree in life sciences from the National Institute of Immunology, New Delhi, India and has authored several original peer-reviewed journal articles. She holds a bachelor’s degree in microbiology and a master’s degree in biomedical sciences both from the University of Delhi, India.

Purchase Report

Recent reports:
You may also be interested in: